KATLIN NADRCHAL: Open Payments
NPI 1689224529 · PAPILLION, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,389 in 79 payments from 19 companies in 2025. Trend: 2023 $1,048 · 2024 $1,150 · 2025 $1,389
Food & beverage: $1,389
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 34 | $465 |
| AstraZeneca Pharmaceuticals LP | 6 | $184 |
| Otsuka America Pharmaceutical, Inc. | 5 | $114 |
| PFIZER INC. | 5 | $78 |
| Vanda Pharmaceuticals Inc. | 4 | $72 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $69 |
| Astellas Pharma US Inc | 2 | $57 |
| Axsome Therapeutics, Inc. | 3 | $54 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $49 |
| Novo Nordisk Inc | 3 | $45 |
Products named: VRAYLAR, REXULTI, QULIPTA, UBRELVY, AIRSUPRA, NURTEC ODT, CAPLYTA, FANAPT.
Industry payments across NE — which companies pay providers there.
